Novavax, Inc.

Equities

NVAX

US6700024010

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-10 pm EDT			5-day change	1st Jan Change
8.120 ^USD	-4.92%		+5.45%	+20.83%

Apr. 09	Sanofi Now Holds Marketing Authorization for COVID-19 Vaccine Nuvaxovid in Canada	MT
Apr. 09	B. Riley Raises Price Target on Novavax to $18 from $16, Keeps Buy Rating	MT

Transcript : Novavax, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 02

Published on 03/03/2026 at 04:06 pm EST - Modified on 03/03/2026 at 04:20 pm EST

S&P Capital IQ

Presenter Speech
Christopher LoBianco (Analysts)

Well, good afternoon, and welcome back to TD Cowen's 46th Annual Healthcare Conference. We're delighted today to be hosting Novavax. And joining me from

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Novavax, Inc.

Apr. 09	Sanofi Now Holds Marketing Authorization for COVID-19 Vaccine Nuvaxovid in Canada	MT
Apr. 09	B. Riley Raises Price Target on Novavax to $18 from $16, Keeps Buy Rating	MT
Apr. 09	US CDC delays publishing report showing COVID vaccine benefits, WaPo reports	RE
Apr. 09	US CDC delays publishing report showing Covid-19 vaccine benefits, Washington Post reports	RE
Apr. 08	Novavax Shareholder Shah Capital to Vote Against Board Nominees, Executive Compensation	MT
Apr. 08	Shah Capital intends to vote against Novavax's board nominees, executive compensation	RE
Mar. 30	Novavax appoints Dr. Robert Walker as executive vice president and head of research & development	RE
Mar. 30	Novavax, Inc. Announces Executive Changes	CI
Mar. 10	Novavax, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 03:40 PM
Mar. 03	Novavax, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 02:30 PM
Feb. 26	Health Care Down Amid Mixed Earnings -- Health Care Roundup	DJ
Feb. 26	Novavax raises revenue forecast on boost from vaccine deals, shares soar	RE
Feb. 26	Keros Therapeutics, Inc. Announces Board Changes, Effective March 9, 2026	CI
Feb. 26	Novavax outlook 2026 adjusted total revenue $230 mln - $270 mln	RE
Feb. 26	Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals	RE